Shandong Boan Biotechnology Croissance future
Future contrôle des critères 2/6
Shandong Boan Biotechnology is forecast to grow revenue at 29% per annum. EPS is expected to decline by 15.9% per annum.
Informations clés
n/a
Taux de croissance des bénéfices
-15.9%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 41.8% |
| Taux de croissance des recettes | 29.0% |
| Rendement futur des capitaux propres | -8.8% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 25 Jul 2024 |
Mises à jour récentes de la croissance future
Pas de mise à jour
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 1,399 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 930 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 723 | N/A | N/A | N/A | 1 |
| 6/30/2024 | 720 | 62 | -442 | -40 | N/A |
| 3/31/2024 | 669 | -29 | -377 | -29 | N/A |
| 12/31/2023 | 618 | -119 | -313 | -19 | N/A |
| 9/30/2023 | 587 | -209 | -338 | -67 | N/A |
| 6/30/2023 | 557 | -298 | -363 | -116 | N/A |
| 3/31/2023 | 536 | -315 | -386 | -159 | N/A |
| 12/31/2022 | 516 | -332 | -408 | -202 | N/A |
| 9/30/2022 | 442 | -291 | -448 | -205 | N/A |
| 6/30/2022 | 367 | -251 | -487 | -209 | N/A |
| 3/31/2022 | 263 | -238 | -537 | -228 | N/A |
| 12/31/2021 | 159 | -225 | -588 | -246 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if 6955's forecast earnings growth is above the savings rate (2.3%).
Bénéfices vs marché: Insufficient data to determine if 6955's earnings are forecast to grow faster than the Hong Kong market
Croissance élevée des bénéfices: Insufficient data to determine if 6955's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 6955's revenue (29% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Croissance élevée des revenus: 6955's revenue (29% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 6955 is forecast to be unprofitable in 3 years.